Crown Bioscience, Inc. has acquired PreClinOmics, Inc., an in vivo preclinical company that specializes in early research in cardiovascular and metabolic diseases (CVMD) as well as renal disease, expanding its portfolio with CVMD models to replicate human disease.   PreClinOmics provides discovery, analytical, and ADME/PK services, safety/non-GLP toxicology services, and genetic models. The acquisition adds highly translational models to effectively screen compounds for efficacy and reduce the...